Meta-analysis of 23 studies (751 patients) in resectable head and neck squamous cell carcinoma: pooled major plus complete pathologic response was 66% with neoadjuvant chemoimmunotherapy vs 18% dual-agent and 6% single-agent immunotherapy.
Meta-analysisn = 751
Baratz et al. Neoadjuvant Immunotherapy and Chemoimmunotherapy Regimens in Head and Neck Cancer: A Systematic Review and Meta-Analysis